» Articles » PMID: 39125749

Enhanced Assessment of Cross-Reactive Antigenic Determinants Within the Spike Protein

Abstract

Despite successful vaccination efforts, the emergence of new SARS-CoV-2 variants poses ongoing challenges to control COVID-19. Understanding humoral responses regarding SARS-CoV-2 infections and their impact is crucial for developing future vaccines that are effective worldwide. Here, we identified 41 immunodominant linear B-cell epitopes in its spike glycoprotein with an SPOT synthesis peptide array probed with a pool of serum from hospitalized COVID-19 patients. The bioinformatics showed a restricted set of epitopes unique to SARS-CoV-2 compared to other coronavirus family members. Potential crosstalk was also detected with Dengue virus (DENV), which was confirmed by screening individuals infected with DENV before the COVID-19 pandemic in a commercial ELISA for anti-SARS-CoV-2 antibodies. A high-resolution evaluation of antibody reactivity against peptides representing epitopes in the spike protein identified ten sequences in the NTD, RBD, and S2 domains. Functionally, antibody-dependent enhancement (ADE) in SARS-CoV-2 infections of monocytes was observed in vitro with pre-pandemic Dengue-positive sera. A significant increase in viral load was measured compared to that of the controls, with no detectable neutralization or considerable cell death, suggesting its role in viral entry. Cross-reactivity against peptides from spike proteins was observed for the pre-pandemic sera. This study highlights the importance of identifying specific epitopes generated during the humoral response to a pathogenic infection to understand the potential interplay of previous and future infections on diseases and their impact on vaccinations and immunodiagnostics.

Citing Articles

Exploring the Contrasts and Similarities of Dengue and SARS-CoV-2 Infections During the COVID-19 Era.

Garcia A, De Sanctis J Int J Mol Sci. 2024; 25(21).

PMID: 39519178 PMC: 11546508. DOI: 10.3390/ijms252111624.

References
1.
Shrock E, Fujimura E, Kula T, Timms R, Lee I, Leng Y . Viral epitope profiling of COVID-19 patients reveals cross-reactivity and correlates of severity. Science. 2020; 370(6520). PMC: 7857405. DOI: 10.1126/science.abd4250. View

2.
Watanabe Y, Hosokawa N, Yoshida M, Miura T, Kawano M . Identification of Closed Linear Epitopes in S1-RBD and S2-HR1/2 of SARS-CoV-2 Spike Protein Able to Induce Neutralizing Abs. Vaccines (Basel). 2023; 11(2). PMC: 9966687. DOI: 10.3390/vaccines11020287. View

3.
Huang Q, Han X, Yan J . Structure-based neutralizing mechanisms for SARS-CoV-2 antibodies. Emerg Microbes Infect. 2022; 11(1):2412-2422. PMC: 9553185. DOI: 10.1080/22221751.2022.2125348. View

4.
Matveeva O, Nechipurenko Y, Lagutkin D, Yegorov Y, Kzhyshkowska J . SARS-CoV-2 infection of phagocytic immune cells and COVID-19 pathology: Antibody-dependent as well as independent cell entry. Front Immunol. 2022; 13:1050478. PMC: 9751203. DOI: 10.3389/fimmu.2022.1050478. View

5.
Piccoli L, Park Y, Tortorici M, Czudnochowski N, Walls A, Beltramello M . Mapping Neutralizing and Immunodominant Sites on the SARS-CoV-2 Spike Receptor-Binding Domain by Structure-Guided High-Resolution Serology. Cell. 2020; 183(4):1024-1042.e21. PMC: 7494283. DOI: 10.1016/j.cell.2020.09.037. View